Guest: Susheel Kodali, M.D.

Susheel Kodali, MD, director of the Structural Heart and Valve Center at NewYork-Presbyterian and Columbia, shares more about an innovative transcatheter therapy for tricuspid regurgitation (TR), which is providing a new treatment option that vastly improves quality of life. Results from the TRISCEND II trial demonstrated the safety and efficacy of a tricuspid valve replacement system, which was fast-tracked for FDA approval due to its clear benefit for the vulnerable TR patient population.

© 2025 NewYork-Presbyterian